COPD
Gilead Sciences Expands into Inflammatory Diseases with $1.7 Billion Collaboration with LEO Pharma
Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25
Actionable Insights Powered by AI
Gilead Sciences, LEO Pharma, STAT6 inhibitors, inflammatory diseases, eczema, asthma, COPD, biotech deal, JPM25